natgillin/translations-raw huggingface dataset:
Each pen contains 3 mL of solution for injection
En napolnjen injekcijski peresnik vsebuje 3 ml raztopine za injiciranje (kar
LUSDUNA 100 units/mL solution for injection in a pre-filled pen Insulin glargine
LUSDUNA 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku insulin glargin
There are no clinically relevant differences in serum insulin or glucose levels after abdominal, deltoid or thigh administration of insulin glargine.
Po injiciranju insulina glargin v trebuh, deltoidni predel ali stegno ni nobenih klinično pomembnih razlik v koncentraciji insulina ali glukoze v serumu.
Medicines that may cause your blood sugar level to fall (hypoglycaemia) include: - all other medicines to treat diabetes, - angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high
Zdravila, ki lahko povzročijo znižanje krvnega sladkorja (hipoglikemijo), so: - vsa druga zdravila za zdravljenje sladkorne bolezni,
In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Okvara ledvic Pri bolnikih z okvaro ledvic se potreba po insulinu lahko zmanjša zaradi zmanjšane presnove insulina.
In healthy subjects and diabetic patients, insulin serum concentrations indicated a slower and much more prolonged absorption and showed a lack of a peak after subcutaneous injection of insulin glargine in comparison to human NPH insulin.
Koncentracija insulina v serumu pri zdravih preiskovancih in diabetikih je po subkutani injekciji insulina glargin v primerjavi s humanim insulinom NPH pokazala počasnejšo in veliko dolgotrajnejšo absorpcijo brez vrha.
LUSDUNA 100 units/mLsolution for injection in a pre-filled pen (Nexvue)
LUSDUNA 100enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku (Nexvue)
For information on the treatment of hypoglycaemia, see section “Hyperglycaemia and Hypoglycaemia” at the end of this leaflet.
Za informacije o zdravljenju hipoglikemije glejte poglavje "Hiperglikemija in hipoglikemija" na koncu tega navodila za
LUSDUNA 100 units/mL injection Nexvue
LUSDUNA 100 enot/ml injekcija Nexvue insulin glargin subkutana uporaba
Test your blood sugar level and your urine for ketones as soon as any of the above symptoms occur.
Takoj, ko se pojavi kateri od zgoraj naštetih simptomov, si izmerite koncentracijo sladkorja v krvi in preverite prisotnost ketonov v urinu.
Insulin glargine
insulin glargin
Attach a new needle
Namestite novo iglo
See section “Hyperglycaemia and Hypoglycaemia” at the end of this leaflet.
Glejte poglavje "Hiperglikemija in hipoglikemija" na koncu tega navodila za uporabo.
- you lose carbohydrates due to vomiting or diarrhoea, - you drink alcohol, particularly if you are not eating much, - you are doing more exercise than usual or a different type of physical activity, - you are recovering from an injury or operation or other stress, - you are recovering from an illness or from fever, - you are taking or have stopped taking certain other medicines (see section 2, "Other medicines and LUSDUNA").
Primeri vključujejo: - injicirate si preveč insulina, - izpustite obroke ali jih imate prepozno, - ne jeste dovolj ali uživate hrano, ki vsebuje manj ogljikovih hidratov kot ponavadi (sladkor in sladkorju podobne snovi imenujemo ogljikovi hidrati; umetna sladila NISO ogljikovi hidrati), - izgubljate ogljikove hidrate zaradi bruhanja ali driske, - pijete alkohol, zlasti če ne jeste dovolj, - ste bolj telesno aktivni kot ponavadi ali je telesna aktivnost drugačna kot po navadi, - okrevate po poškodbi, operaciji ali drugem stresu, - okrevate po bolezni ali zvišani telesni temperaturi, - jemljete ali ste nehali jemati določena druga zdravila (glejte poglavje 2, "Druga zdravila in zdravilo LUSDUNA").
When given intravenously the elimination half-life of insulin glargine and human insulin were comparable.
Po intravenski uporabi je eliminacijski razpolovni čas insulina glargin podoben eliminacijskemu razpolovnemu času humanega insulina.
Dose
Glejte
LUSDUNA contains insulin glargine.
Zdravilo LUSDUNA vsebuje insulin glargin.
Put used needles in a closeable, puncture-resistant sharps container.
Uporabljene igle dajte v vsebnik, ki je odporen proti prebadanju in ga je mogoče zapreti.
This pen allows you to dial a dose between 1-60 units.
Ta injekcijski peresnik omogoča nastavitev odmerka od 1
Talk to your doctor, pharmacist or nurse before using LUSDUNA.
Pred začetkom uporabe zdravila LUSDUNA se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Remove inner needle cap and throw away
Odstranite notranji pokrovček igle in ga zavrzite.
For more information, see section “Hyperglycaemia and Hypoglycaemia” at the end of this leaflet.
Za več informacij glejte poglavje "Hiperglikemija in hipoglikemija" na koncu tega navodila za uporabo.
Your blood sugar level may either rise or fall if you take: - beta-blockers (used to treat high blood pressure), - clonidine (used to treat high blood pressure), - lithium salts (used to treat psychiatric disorders).
Vaš krvni sladkor se lahko zviša ali zniža, če jemljete: - antagoniste adrenergičnih receptorjev beta (uporabljajo se za zdravljenje visokega krvnega
Oedema
Odmerek
LUSDUNA 100 units/mL solution for injection in a pre-filled pen
LUSDUNA 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Do a safety check each time you inject.
Pred vsakim injiciranjem opravite varnostni preizkus.
The longer duration of action of subcutaneous insulin glargine is directly related to its slower rate of absorption and supports once daily administration.
Dolgotrajnejše delovanje subkutanega insulina glargin je neposredno povezano z njegovo počasnejšo absorpcijo in podpira uporabo enkrat na dan. Časovni potek delovanja insulina in insulinskih analogov, kot je insulin glargin, se lahko zelo razlikuje tako med posamezniki kot pri eni in isti osebi.
Recap the pen after use in order to protect from light.
Po uporabi namestite pokrovček injekcijskega peresnika nazaj na peresnik za zagotovitev zaščite pred svetlobo.
Getting ready
Priprava
5 pre-filled pens of 3 mL.
5 napolnjenih injekcijskih peresnikov s 3 ml. Del multi pakiranja, ni za posamično prodajo.
Solution for injection.
Shranjevanje injekcijskega peresnika
Give the injection
Injicirajte
- your insulin pen does not work properly, - you are doing less exercise than usual, you are under stress (emotional distress, excitement), or you have an injury, operation, infection or fever, - you are taking or have taken certain other medicines (see section 2, "Other medicines and
operacija, okužba ali zvišana telesna temperatura, - jemljete ali ste jemali določena druga zdravila (glejte poglavje 2, "Druga zdravila in zdravilo
The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if - you are elderly, if you have had diabetes for a long time or if you suffer from a certain type of nervous disease (diabetic autonomic neuropathy), - you have recently suffered hypoglycaemia (for example the day before) or if it develops slowly, - you have almost normal or, at least, greatly improved blood sugar levels, - you have recently changed from an animal insulin to a human insulin such as LUSDUNA, - you are taking or have taken certain other medicines (see section 2, "Other medicines and
- če imate skoraj normalno ali vsaj močno izboljšano koncentracijo krvnega sladkorja, - če ste pred kratkim prešli z živalskega insulina na humani insulin, kot je zdravilo LUSDUNA, - če jemljete ali ste jemali določena druga zdravila (glejte poglavje 2, "Druga zdravila in zdravilo
• General disorders
• Splošne težave
Retinopathy
Dojenje
Insulin cartridge dose window injection button
telo peresnika gumb za nastavitev vložek z insulinom okence odmerka gumb za injiciranje zunanji pokrovček igle notranji pokrovček igle
The pen won't let you dial past the number of insulin units left in the pen.
Injekcijski peresnik onemogo a nastavitev odmerka, ki je ve ji od števila preostalih enot insulina v njem.
Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins.
Da bi se izognili napakam pri uporabi zdravila zaradi zamenjave med insulinom glargin in drugimi insulini, je treba pred vsakim injiciranjem preveriti označevanje insulina.
Your abdomen, thigh, or back of your upper arm, are the best sites for injection.
Najprimernejša mesta za injiciranje so trebuh, stegno in zadnji del nadlakti.
See section 4.
do 60 enot.
The cartridge is sealed in a disposable pen injector.
Vložek je zapečaten v injekcijski peresnik, ki se po končani uporabi zavrže.
Carefully read the instructions for use included in the package before using Nexvue.
Pred uporabo napolnjenega injekcijskega peresnika Nexvue natančno preberite navodila za njegovo uporabo, priložena v pakiranju.
There was one death in each group (less than 1%).
V vsaki skupini je umrla ena oseba (manj kot 1 %).
Further information on Pradaxa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Nadaljnje informacije o zdravilu Pradaxa so na voljo na spletni strani agencije:ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
In the study, around 18,000 adults were treated for one to three years.
V študiji so približno 18 000 odraslih zdravili od enega do treh let.
What measures are being taken to ensure the safe and effective use of Pradaxa?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pradaxa?
Pradaxa received a marketing authorisation valid throughout the EU on 18 March 2008.
Za zdravilo Pradaxa je bilo 18. marca 2008 izdano dovoljenje za promet, veljavno po vsej EU.
Patients will also receive an alert card summarising key safety information on the medicine.
Bolniki bodo prejeli tudi opozorilno kartico, ki povzema ključne varnostne informacije o tem zdravilu.
Pradaxa is an anticoagulant medicine used for:
Pradaxa je antikoagulantno zdravilo, ki se uporablja za:
This means that it is converted into dabigatran in the body.
To pomeni, da se šele v telesu pretvori v dabigatran.
Therefore the European Medicines Agency decided that Pradaxa's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Pradaxa večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
It blocks a substance called thrombin, which is central to the process of blood clotting.
Zavira snov, imenovano trombin, ki je ključna za proces strjevanja krvi.
Other information about Pradaxa
Druge informacije o zdravilu Pradaxa
Why is Pradaxa authorised in the EU?
Zakaj je bilo zdravilo Pradaxa odobreno v EU?
As for all medicines, data on the use of Pradaxa are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Pradaxa stalno spremljajo.
In both studies, there was some evidence that a 220 mg dose of Pradaxa may be more effective than a 150 mg dose.
V obeh študijah je bilo nekaj dokazov, da je lahko 220-miligramski odmerek zdravila Pradaxa učinkovitejši od 150-miligramskega.
It must not be used in patients taking any other anticoagulant medicine, except when the anticoagulant medicine is being switched or when heparin (another anticoagulant medicine) is being used in specific medical procedures.
Ne sme se uporabljati pri bolnikih, ki jemljejo kateri koli drugi antikoagulant, razen kadar se antikoagulant zamenja ali kadar se pri posameznih medicinskih posegih uporablja heparin (drugi antikoagulant).
What benefits of Pradaxa have been shown in studies?
Kakšne koristi zdravila Pradaxa so se pokazale v študijah?
Three patients in the Pradaxa group died (less than 1%), but two of these deaths were unrelated to blood clots.
V skupini, ki je prejemala zdravilo Pradaxa, so umrli trije bolniki (manj kot 1 %), vendar dve od teh smrti nista bili povezani s krvnimi strdki.
Dabigatran is an anticoagulant, meaning that it prevents the blood from coagulating (clotting).
Dabigatran je antikoagulant, kar pomeni, da preprečuje koagulacijo (strjevanje) krvi.
All patients at increased risk of bleeding should be monitored closely and the doctor may reduce the dose of Pradaxa.
Vse bolnike s povečanim tveganjem za krvavitev je treba natančno spremljati, zdravnik pa lahko odmerek zdravila Pradaxa tudi zmanjša.
The company that makes Pradaxa will provide an educational pack for all doctors who are expected to prescribe the medicine, to increase awareness of the risk of bleeding and provide guidance on how to manage it.
Podjetje, ki izdeluje zdravilo Pradaxa, bo pripravilo izobraževalno gradivo za vse zdravnike, ki bodo predpisovali zdravilo, in tako povečalo ozaveščenost o tveganjih za krvavitve ter zagotovilo smernice za njihovo obvladovanje.
An overview of Pradaxa and why it is authorised in the EU
Pregled zdravila Pradaxa in zakaj je odobreno v EU
These clots, present in conditions such as deep vein thrombosis (DVT), can be dangerous if they move to another part of the body such as the lungs.
Ti strdki, ki so prisotni pri boleznih, kot je globoka venska tromboza, so lahko nevarni, če se premaknejo v drug del telesa, npr. v pljuča.
What are the risks associated with Pradaxa?
Kakšna tveganja so povezana z zdravilom Pradaxa?
The dose and duration of treatment depend on the condition Pradaxa is being used to treat, the patient's age and kidney function, and other medicines the patient is taking.
Odmerek in trajanje zdravljenja sta odvisna od bolezni, za zdravljenje katere se zdravilo Pradaxa uporablja, bolnikove starosti in delovanja ledvic ter drugih zdravil, ki jih bolnik jemlje.
Pradaxa is available as capsules (75, 110 and 150 mg) and can only be obtained with a prescription.
Zdravilo Pradaxa je na voljo v obliki kapsul (75 mg, 110 mg in 150 mg), njegovo predpisovanje in izdaja pa je le na recept.
The most common side effect with Pradaxa (which may affect more than 1 in 10 people) is bleeding.
Najpogostejši neželeni učinek zdravila Pradaxa (ki se lahko pojavi pri več kot 1 bolniku od 10 ), je krvavitev.
Since certain patients who take Pradaxa are at increased risk of bleeding, a number of precautions were included in the prescribing information.
Ker so nekateri bolniki, ki jemljejo zdravilo Pradaxa, izpostavljeni povečanemu tveganju za krvavitve, so bili v informacije o predpisovanju vključeni številni previdnostni ukrepi.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pradaxa have also been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Pradaxa upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
For more information about using Pradaxa, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Pradaxa glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Side effects reported with Pradaxa are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Pradaxa, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Patients who have atrial fibrillation are also at risk of blood clots which can travel to the brain and cause a stroke.
Pri bolnikih z atrijsko fibrilacijo prav tako obstaja tveganje za nastanek krvnih strdkov, ki lahko pridejo do možganov in povzročijo možgansko kap.
• treating deep vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg) and pulmonary embolism (PE, a clot in a blood vessel supplying the lungs) in adults, and preventing these conditions from occurring again.
• zdravljenje globoke venske tromboze (DVT, krvnega strdka v globoki veni, običajno v nogi) in pljučne embolije (strdka v krvni žili, ki oskrbuje pljuča) ter preprečevanje njune ponovitve pri odraslih.
Although the studies showed a small higher risk of heart problems with Pradaxa than with warfarin, the benefits of Pradaxa were still considered to outweigh its risks.
Čeprav so študije pokazale, da je ob jemanju zdravila Pradaxa tveganje za težave s srcem nekoliko večje kot pri varfarinu, še vedno velja, da koristi zdravila Pradaxa odtehtajo z njim povezana tveganja.
What is Pradaxa and what is it used for?
Kaj je zdravilo Pradaxa in za kaj se uporablja?
The first study involved a total of 2,101 patients who had had a knee replacement operation.
V prvo študijo je bilo vključenih skupno 2 101 bolnikov, katerim je bilo kirurško vstavljeno umetno koleno.
Pradaxa must also not be used in patients with serious liver problems or in patients being treated with certain medicines.
Zdravilo Pradaxa se tudi ne sme uporabljati pri bolnikih z resnimi težavami z jetri ali tistih, ki se zdravijo z določenimi zdravili.
Pradaxa compared well with warfarin in reducing the risk of strokes in patients with atrial fibrillation without increasing the risk of major bleeding.
Zdravilo Pradaxa je dobro primerljivo z varfarinom pri zmanjševanju tveganja za možgansko kap pri bolnikih z atrijsko fibrilacijo, ne da bi se pri tem povečalo tveganje za večje krvavitve.
When Pradaxa is used long term in patients with non-valvular atrial fibrillation, or when it is used in patients with DVT or PE, kidney function should be assessed at least once a year if their kidney function is mildly to moderately reduced or if they are over 75 years old.
Če se zdravilo Pradaxa dolgotrajno uporablja pri bolnikih z atrijsko fibrilacijo brez okvare srčnih zaklopk ali če se uporablja pri bolnikih z globoko vensko trombozo ali pljučno embolijo, je treba delovanje njihovih ledvic v primeru, da imajo blago do zmerno ledvično okvaro ali če so starejši od 75 let, oceniti vsaj enkrat na leto.
Pradaxa, which is taken by mouth, is more convenient for patients.
Zdravilo Pradaxa, ki se jemlje peroralno, je za bolnike bolj priročno.
One of these studies compared Pradaxa with warfarin and the other compared Pradaxa with placebo (a dummy treatment).
V eni od teh študij so zdravilo Pradaxa primerjali z varfarinom, v drugi pa s placebom (zdravilom brez učinkovine).
• preventing stroke and the formation of clots in adults who have an abnormal heartbeat called ‘nonvalvular atrial fibrillation' and are considered to be at risk of stroke;
• preprečevanje kapi in nastajanja krvnih strdkov pri odraslih z motnjami srčnega utripa, imenovanimi „atrijska fibrilacija brez okvare srčnih zaklopk“, in pri katerih obstaja tveganje za kap;
Another two studies looked at the prevention of VTE or PE in around 4,200 adults with symptoms of recurring blood clots and who were on long-term treatment with anticoagulants.
V dveh drugih študijah so proučevali preprečevanje globoke venske tromboze ali pljučne embolije pri okoli 4 200 odraslih bolnikih s simptomi ponavljajočih se krvnih strdkov, ki so se dolgotrajno zdravili z antikoagulanti.
However, the number of bleeding events was lower for Pradaxa than for warfarin.
Kljub temu je bilo število epizod krvavitve pri uporabi zdravila Pradaxa manjše kot pri uporabi varfarina.
Two main studies in over 5,100 adults with symptoms of DVT or PE, and who were initially treated with an injectable anticoagulant, compared Pradaxa with warfarin.
V dveh glavnih študijah, v katerih je sodelovalo več kot 5 100 odraslih bolnikov s simptomi globoke venske tromboze ali pljučne embolije, ki so bili najprej zdravljeni z injekcijami antikoagulantov, so zdravilo Pradaxa primerjali z varfarinom.
The second study involved a total of 3,494 patients who had had a hip replacement.
V drugo študijo je bilo vključenih skupno 3 494 bolnikov, pri katerih je bila opravljena kirurška vstavitev umetnega kolka.
Prevention of blood clots after hip or knee replacement
Preprečevanje krvnih strdkov po vstavitvi kolka ali kolena
Pradaxa must not be used in patients who have severely reduced kidney function, who are currently bleeding significantly or who have a condition putting them at significant risk of major bleeding.
Zdravilo Pradaxa se ne sme uporabljati pri bolnikih, ki imajo hudo ledvično okvaro, obilno krvavitev ali stanje, zaradi katerega so izpostavljeni precejšnjemu tveganju za večje krvavitve.
Prevention of blood clots or stroke in patients at risk of stroke
Preprečevanje krvnih strdkov ali kapi pri bolnikih s tveganjem za možgansko kap
How is Pradaxa used?
Kako se zdravilo Pradaxa uporablja?
Pradaxa contains the active substance dabigatran etexilate.
Zdravilo Pradaxa vsebuje učinkovino dabigatran eteksilat.
How does Pradaxa work?
Kako zdravilo Pradaxa deluje?
In all patients, kidney function should also be assessed before starting treatment to exclude patients with severely reduced kidney function, and should be re-assessed during treatment if any worsening is suspected.
Pri vseh bolnikih je treba pred začetkom zdravljenja oceniti tudi delovanje ledvic, da se izključijo bolniki s hudo ledvično okvaro.
• preventing the formation of blood clots in the veins in adults who have had an operation to replace a hip or knee;
• preprečevanje nastajanja krvnih strdkov v venah pri odraslih po operativni vstavitvi umetnega kolka ali kolena;
For the full list of all side effects reported with Pradaxa, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Pradaxa, glejte navodilo za uporabo.
Pradaxa (220 or 150 mg a day) was as effective as enoxaparin (an anticoagulant given by injection) in preventing formation of blood clots or death in patients who had undergone hip or knee replacement in two main studies.
Zdravilo Pradaxa (220 mg ali 150 mg na dan) je bilo v dveh študijah enako učinkovito kot enoksaparin (antikoagulant, ki se daje z injekcijo) pri preprečevanju nastajanja krvnih strdkov ali smrti pri bolnikih, pri katerih je bila opravljena vstavitev kolka ali kolena.
Pradaxa (110 mg or 150 mg twice a day) was as effective as warfarin (another anticoagulant given by mouth) in preventing stroke or a blood clot blocking blood vessels in other parts of the body in a study of patients with non-valvular atrial fibrillation who were considered to be at risk of stroke.
Zdravilo Pradaxa (110 mg ali 150 mg dvakrat na dan) je bilo pri preprečevanju možganske kapi ali zamašitve krvnih žil s krvnim strdkom v drugih delih telesa pri bolnikih z atrijsko fibrilacijo, ki ni povezana s srčnimi zaklopkami, pri katerih naj bi obstajalo tveganje za kap, enako učinkovito kot varfarin (drug antikoagulant, ki se jemlje peroralno).
In addition, the overall benefit of Pradaxa in the treatment and prevention of DVT and PE is comparable to that of warfarin.
Poleg tega so skupne koristi zdravila Pradaxa pri zdravljenju in preprečevanju globoke venske tromboze in pljučne embolije primerljive koristim varfarina.
The proportion of patients who had a stroke or other problems caused by blood clots each year was around 1.5% for patients taking 110 mg Pradaxa (183 patients out of 6,015) and 1.1% for patients taking 150 mg Pradaxa (135 out of 6,076), compared with 1.7% for patients taking warfarin (203 out of 6,022).
Delež bolnikov, ki so vsako leto imeli možgansko kap ali drugo težavo, povezano s krvnimi strdki, je bil okoli 1,5 % (183 od 6 015) pri tistih bolnikih, ki so jemali zdravilo Pradaxa v odmerku 110 mg, in 1,1 % (135 od 6 076) pri tistih, ki so jemali zdravilo Pradaxa v odmerku 150 mg, v primerjavi z 1,7 % (203 od 6 022) pri bolnikih, ki so jemali varfarin.
The active substance in Pradaxa, dabigatran etexilate, is a ‘prodrug' of dabigatran.
Učinkovina v zdravilu Pradaxa, dabigatran eteksilat, je predzdravilo dabigatrana.
Patients undergoing hip or knee replacement surgery are at a high risk of blood clots forming in their leg veins.
Pri bolnikih, pri katerih se izvede operativna vstavitev umetnega kolka ali kolena, obstaja veliko tveganje za nastanek krvnih strdkov v venah nog.